SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Enalaprilat Injection, USP (Hospira Inc.)

Trade Name: Enalaprilat Injection, USP

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product for the treatment of high blood pressure (hypertension)

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A

Label Elements

Signal Word: Danger

Hazard Statements: H360D - May damage the unborn child

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enalaprilat Dihydrate</td>
<td>84680-54-6</td>
<td>Not Listed</td>
<td>Repr 1A (H360D)</td>
<td>0.125</td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>Skin Corr. 1A (H314)</td>
<td>**</td>
</tr>
<tr>
<td>BENZYL ALCOHOL</td>
<td>100-51-6</td>
<td>202-859-9</td>
<td>Acute Tox. 4 (H302)</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

- * Proprietary
- ** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: May include oxides of carbon.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Incompatible Materials: None known

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.
Safeguards

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Substance</th>
<th>OEB 3 (control exposure to the range of 10ug/m³ to &lt; 100ug/m³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. Exposure Controls</td>
<td>Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.</td>
</tr>
<tr>
<td>Personal Protective Equipment</td>
<td>Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).</td>
</tr>
<tr>
<td>Hands</td>
<td>Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)</td>
</tr>
<tr>
<td>Eyes</td>
<td>Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)</td>
</tr>
</tbody>
</table>
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Odor: No data available.
Molecular Formula: Mixture
Solvent Solubility: No data available
Water Solubility: Soluble
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

BENZYL ALCOHOL
No data available

Water for Injection
No data available

SODIUM CHLORIDE
No data available

SODIUM HYDROXIDE
No data available

Enalaprilat Dihydrate
No data available

Decomposition Temperature (°C): No data available

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
  Autoignition Temperature (Solid) (°C): No data available
  Flammability (Solids): No data available
  Flash Point (Liquid) (°C): No data available
  Upper Explosive Limits (Liquid) (% by Vol.): No data available
  Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: None
  Conditions to Avoid: None known
**SAFETY DATA SHEET**

**Material Name:** Enalaprilat Injection, USP (Hospira Inc.)

**Revision date:** 03-Aug-2016

**Version:** 1.0

---

### 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Incompatible Materials:</th>
<th>None known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hazardous Decomposition Products:</td>
<td>None known</td>
</tr>
</tbody>
</table>

---

### 11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Long Term:** In humans, the use of drugs in this class (ACE inhibitors) can cause fetal and neonatal toxicity, including low blood pressure and kidney failure, when they are taken during the second and third trimesters of pregnancy.

**Known Clinical Effects:** Adverse effects most commonly reported in clinical use include cough, loss of taste, diarrhea, nausea, headache, tiredness, dizziness, fever, joint pain, skin rash, fainting (syncope).

**Acute Toxicity:** (Species, Route, End Point, Dose)

**BENZYL ALCOHOL**
- Rat Oral LD 50 1230 mg/kg
- Mouse Oral LD 50 1360mg/kg
- Rabbit Dermal LD 50 2gm/kg

**SODIUM CHLORIDE**
- Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
- Rat Oral LD 50 3g/kg
- Mouse Oral LD 50 4g/kg
- Rabbit Dermal LD 50 > 10g/kg

**Enalaprilat Dihydrate**
- Rat Oral LD50 2973 mg/kg
- Mouse Oral LD50 3507mg/kg
- Rat Intravenous LD50 849mg/kg
- Mouse Intravenous LD50 859mg/kg

**Irritation / Sensitization:** (Study Type, Species, Severity)

**SODIUM CHLORIDE**
- Skin Irritation Rabbit Mild
- Eye Irritation Rabbit Mild

**Reproduction & Development Toxicity:** (Duration, Species, Route, Dose, End Point, Effect(s))

**Enalaprilat Dihydrate**
- Reproductive & Fertility Rat No route specified90 mg/kg/day NOAEL No effects at maximum dose
- Embryo / Fetal Development Rabbit Oral 12 times human dose NOAEL Not Teratogenic
- Embryo / Fetal Development Rat Oral 57 times human dose NOAEL Not Teratogenic

**Genetic Toxicity:** (Study Type, Cell Type/Organism, Result)

**Enalaprilat Dihydrate**
- Bacterial Mutagenicity (Ames) Negative
- Micronucleus Mouse Negative
- In Vivo Cytogenetics Mouse Bone Marrow Negative

PZ03088
11. TOXICOLOGICAL INFORMATION

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

<table>
<thead>
<tr>
<th>Material Name: Enalaprilat Injection, USP (Hospira Inc.)</th>
</tr>
</thead>
</table>

**Enalaprilat Dihydrate**

- 106 Week(s) Female Male Rat No route specified 90 mg/kg/day NOAEL Not carcinogenic
- 94 Week(s) Male Mouse No route specified 90 mg/kg/day NOAEL Not carcinogenic
- 94 Week(s) Female Mouse No route specified 180 mg/kg/day NOAEL Not carcinogenic

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

**Toxicity:**

**Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

**BENZYL ALCOHOL**

- Fathead Minnow NPDES LC-50 96 Hours 460 - 770 mg/L
- Bluegill NPDES LC-50 96 Hours 10 mg/L
- *Daphnia Magna* (Water Flea) Surrogate ErC50 48 Hours 23 - 400 mg/L

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Water for Injection
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 231-791-2

Enalaprilat Dihydrate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- EU EINECS/ELINCS List: Not Listed

SODIUM HYDROXIDE
- CERCLA/SARA 313 Emission reporting: Not Listed
- CERCLA/SARA Hazardous Substances and their Reportable Quantities: 1000 lb, 454 kg
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 5, Schedule 6
- EU EINECS/ELINCS List: 215-185-5

BENZYL ALCOHOL
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 202-859-9

SODIUM CHLORIDE
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 231-598-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
SAFETY DATA SHEET

Material Name: Enalaprilat Injection, USP (Hospira Inc.)
Revision date: 03-Aug-2016

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled
Reproductive toxicity-Cat.1A; H360D - May damage the unborn child

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 03-Aug-2016
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet